{"nctId":"NCT00319020","briefTitle":"Bosentan in Children With Pulmonary Arterial Hypertension Extension Study","startDateStruct":{"date":"2005-08-23","type":"ACTUAL"},"conditions":["Pulmonary Arterial Hypertension"],"count":33,"armGroups":[{"label":"Bosentan","type":"EXPERIMENTAL","interventionNames":["Drug: Bosentan"]}],"interventions":[{"name":"Bosentan","otherNames":["Ro 47-0203","Tracleer"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Signed informed consent by the parents or the legal representatives.\n* Patients who completed the FUTURE 1 study.\n* Patients who tolerated bosentan pediatric formulation and for whom bosentan is considered beneficial at the end of FUTURE 1.\n* Males or females \\>= 2 and \\< 12 years of age at enrollment in FUTURE 2 (this study). Females who are menstruating must have a negative pregnancy test. A reliable method of contraception must be considered, if appropriate.\n\nExclusion Criteria:\n\n* Intolerance to bosentan despite dose reductions.\n* Any clinically significant laboratory abnormality that precludes continuation of bosentan therapy.\n* Pregnancy or breast-feeding.\n* Known hypersensitivity to bosentan or any of the excipients.\n* Premature and permanent study drug discontinuation during FUTURE 1.","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","maximumAge":"11 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline to End of Study (EOS) in Height for Age.","description":"In order to compare the growth data with those of healthy children, growth curves are calculated from height data collected throughout the follow-up period. For each patient, height measured at each study visit was converted to a z-score and expressed in standard deviations (SD) from WHO growth standards. The Z-score was calculated according to the following formula:\n\nZ-score = (observed value of the study participant - median value of the reference population) / SD value of the reference population","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":null},{"groupId":"OG001","value":"0.32","spread":null},{"groupId":"OG002","value":"-0.64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.74","spread":null},{"groupId":"OG001","value":"-0.08","spread":null},{"groupId":"OG002","value":"-0.36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.05","spread":null},{"groupId":"OG001","value":"-0.01","spread":null},{"groupId":"OG002","value":"-0.01","spread":null}]}]}]},{"type":"PRIMARY","title":"Change From Baseline to End of Study (EOS) in Body Weight","description":"The main study objective was to assess the long-term safety and tolerability of bosentan in children with PAH, including growth as measured by changes from baseline in body weight and height.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.6","spread":null},{"groupId":"OG001","value":"21.6","spread":null},{"groupId":"OG002","value":"19.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":null},{"groupId":"OG001","value":"8.5","spread":null},{"groupId":"OG002","value":"8.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Change From Baseline to End of Study (EOS) in Systolic Blood Pressure (SBP)","description":"The main study objective was to assess the long-term safety and tolerability of bosentan in children with PAH, including changes from baseline in blood pressure.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"101.5","spread":null},{"groupId":"OG001","value":"104","spread":null},{"groupId":"OG002","value":"102.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.5","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"-4.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Change From Baseline to End of Study (EOS) in Diastolic Blood Pressure (DBP)","description":"The main study objective was to assess the long-term safety and tolerability of bosentan in children with PAH, including changes from baseline in blood pressure.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.5","spread":null},{"groupId":"OG001","value":"60","spread":null},{"groupId":"OG002","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5","spread":null},{"groupId":"OG001","value":"-2","spread":null},{"groupId":"OG002","value":"-3","spread":null}]}]}]},{"type":"PRIMARY","title":"Change From Baseline to End of Study (EOS) in Pulse Rate","description":"The main study objective was to assess the long-term safety and tolerability of bosentan in children with PAH, including changes from baseline in pulse rate.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"94.5","spread":null},{"groupId":"OG002","value":"88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11","spread":null},{"groupId":"OG001","value":"-10","spread":null},{"groupId":"OG002","value":"-11","spread":null}]}]}]},{"type":"PRIMARY","title":"Proportion of Patients With Treatment-emergent Liver Function Abnormalities","description":"The main study objective was to assess the long-term safety and tolerability of bosentan in children with PAH, including laboratory abnormalities related to liver enzymes.\n\nProportion of patients with increase in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) above 3 times upper limit of normal (ULN) is reported here.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"4.8","spread":null},{"groupId":"OG002","value":"2.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"4.8","spread":null},{"groupId":"OG002","value":"2.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Proportion of Patients With Treatment-emergent Hemoglobin Abnormalities","description":"The main study objective was to assess the long-term safety and tolerability of bosentan in children with PAH, including hemoglobin abnormalities.\n\nProportion of patients with marked hemoglobin decreases (i.e., decrease of or above 15% of the lower normal limit (LL)) is reported here.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.3","spread":null},{"groupId":"OG001","value":"9.5","spread":null},{"groupId":"OG002","value":"11.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Adverse Events Leading to Premature Discontinuation of Study Treatment","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":15},"commonTop":["NASOPHARYNGITIS","ABDOMINAL PAIN","BRONCHITIS","UPPER RESPIRATORY TRACT INFECTION","FLUSHING"]}}}